Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Progenics Pharmaceuticals, a biopharmaceutical company, has appointed Peter Crowley as an independent director to its board of directors.
Subscribe to our email newsletter
A senior healthcare investment banker with over 20 years’ experience in the industry, Mr Crowley will also serve on the company’s audit committee. Mr Crowley retired in 2008 from a 23-year career at CIBC World Markets, where he headed healthcare investment banking since 1995.
Mr Crowley holds an undergraduate degree in economics from Harvard University and an MBA in finance from Columbia University’s Graduate School of Business.
Paul Maddon, CEO and chief science officer of Progenics, said: “Peter is a respected member of the financial community who has worked extensively with Progenics in past years, enabling significant contributions to our success.
“His industry expertise and business acumen will be invaluable as we select strategies to advance our virology and oncology programs and further the company’s development. I welcome Peter to our team and look forward to working with him in his new role.”